The Pharmacokinetics of a Hemp-Based Topical Product

Starting soon · Phase 1

Conditions studied: Cannabis

In brief

This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.

Key facts

Study ID

NCT07603518

Run by

Johns Hopkins University

People needed

20

Starts

2026-06-01

Expected to finish

2026-09-01

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Have provided written informed consent
• Be between the ages of 18 and 55
• Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
• Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.
• Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.
• Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.
• Have a body mass index (BMI) in the range of 18 to 38 kg/m2
• Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
• Report prior experience using cannabis or CBD products.

You may not qualify if…

• Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.
• History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
• Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.
• History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
• Known allergy to any ingredients in the study drug.
• Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.

Where it is running

• Behavioral Pharmacology Research Unit — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.